Analyze Diet
Veterinary ophthalmology2009; 12 Suppl 1; 10-16; doi: 10.1111/j.1463-5224.2009.00740.x

Equine immune-mediated keratopathies.

Abstract: Equine immune mediated keratopathies are common in both Europe and the USA. This review article will compare the clinical differences in horses with this disease and also review the current theories on pathogenesis and treatment of equine IMMK.
Publication Date: 2009-11-26 PubMed ID: 19891646DOI: 10.1111/j.1463-5224.2009.00740.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article primarily delves into the subject of equine immune-mediated keratopathies (IMMK) – a frequently occuring condition in horses, primarily in Europe and the USA – assessing its clinical differences displayed in affected horses, along with discussing the prevalent theories concerning its origin and potential treatments.

Understanding Equine immune-mediated keratopathies (IMMK)

Equine immune-mediated keratopathies (IMMK) are diseases affecting the cornea of horses. The cornea is the clear front surface of the eye that allows light to enter. When it is affected by IMMK, it may lead to discomfort, impaired vision, or more severe consequences like corneal ulcers. These diseases are not rare and occur widely in horses across Europe and the USA.

  • The term ‘immune-mediated’ relates to the fact that these diseases are likely caused by the body’s own immune system responding inappropriately to some perceived threat.
  • Despite being grouped under a single term, equine IMMK includes several different conditions that can affect the cornea of horses. Each of these conditions can show different symptoms, progress in different ways, and respond to different treatments.

Clinical Differences in Horses with IMMK

The authors of the article compared the clinical manifestations of IMMK in different horses. Clinical differences might include variation in symptoms, disease progression, or response to treatment.

  • For example, some horses may exhibit redness, swelling, and discomfort in the affected eye(s), while others might have different symptoms such as cloudiness of the cornea or reduced vision.
  • These variations can be influenced by numerous factors, including the specific disease causing the IMMK, the horse’s individual immune system, and its overall health status.

Theories on Pathogenesis and Treatment of Equine IMMK

The researchers also explored current theories about the pathogenesis (origin and development) and treatment of equine IMMK.

  • A key point in this section is the belief that these diseases are caused by the body’s own immune system responding incorrectly, often to an unknown trigger.
  • The focus of treatment usually circles around suppressing the immune system’s response, preventing further damage to the cornea, and allowing the eye to heal. Medicines, like steroids, might be utilized for this purpose, although this approach also has its downsides such as potential side effects.
  • The article might also discuss alternative treatments, like surgical interventions or newly emerging methods that show promise in the treatment of equine IMMK.

Cite This Article

APA
Matthews A, Gilger BC. (2009). Equine immune-mediated keratopathies. Vet Ophthalmol, 12 Suppl 1, 10-16. https://doi.org/10.1111/j.1463-5224.2009.00740.x

Publication

ISSN: 1463-5224
NlmUniqueID: 100887377
Country: England
Language: English
Volume: 12 Suppl 1
Pages: 10-16

Researcher Affiliations

Matthews, Andrew
  • McKenzie Bryson and Marshall, 21 Hill Street, Kilmarnock, UK.
Gilger, Brian C

    MeSH Terms

    • Animals
    • Horse Diseases / immunology
    • Horse Diseases / pathology
    • Horses
    • Keratitis / immunology
    • Keratitis / pathology
    • Keratitis / veterinary

    References

    This article includes 23 references

    Citations

    This article has been cited 3 times.
    1. Cassano JM, Leonard BC, Martins BC, Vapniarsky N, Morgan JT, Dow SW, Wotman KL, Pezzanite LM. Preliminary evaluation of safety and migration of immune activated mesenchymal stromal cells administered by subconjunctival injection for equine recurrent uveitis. Front Vet Sci 2023;10:1293199.
      doi: 10.3389/fvets.2023.1293199pubmed: 38162475google scholar: lookup
    2. Padjasek M, Cisło-Sankowska A, Lis-Bartos A, Qasem B, Marycz K. PLDLA/TPU Matrix Enriched with Cyclosporine A as a Therapeutic Platform for Immune-Mediated Keratitis (IMMK) in Horses. Int J Mol Sci 2023 Mar 17;24(6).
      doi: 10.3390/ijms24065735pubmed: 36982806google scholar: lookup
    3. Padjasek M, Qasem B, Cisło-Pakuluk A, Marycz K. Cyclosporine A Delivery Platform for Veterinary Ophthalmology-A New Concept for Advanced Ophthalmology. Biomolecules 2022 Oct 20;12(10).
      doi: 10.3390/biom12101525pubmed: 36291734google scholar: lookup